Page 83 - Read Online

influence of glioma. Neuro Oncol 2012;14:958-78. 102. Kruse CA, Rubinstein D. Cytotoxic T lymphocytes reactive to patient
90. Li W, Holsinger RM, Kruse CA, Flugel A, Graeber MB. The potential major histocompatibility proteins for therapy of recurrent primary
for genetically altered microglia to influence glioma treatment. CNS brain tumors. In: Liau LM, Cloughesy TF, Becker DP, Bigner DD,
Neurol Disord Drug Targets 2013;12:750-62. editors; Brain tumor immunotherapy. Totowa: Humana Press 2001.
91. Smallie T, Ricchetti G, Horwood NJ, Feldmann M, Clark AR, p. 149-70.
Williams LM. IL-10 inhibits transcription elongation of the human 103. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO.
TNF gene in primary macrophages. J Exp Med 2010;207:2081-8. Treatment of recurrent glioma with intracavitary alloreactive
92. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 cytotoxic T lymphocytes and interleukin-2. Cancer Immunol
inhibits nuclear factor kappa B (NF kappa B) activation in human Immunother 1997;45:77-87.
monocytes. IL-10 and IL-4 suppress cytokine synthesis by different 104. Logg CR, Kasahara N. Retrovirus-mediated gene transfer to tumors:
mechanisms. J Biol Chem 1995;270:9558-63. utilizing the replicative power of viruses to achieve highly efficient
93. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, tumor transduction in vivo. Meth Mol Biol 2004;246:499-525.
Bottazzi B, Colombo MP, Mantovani A, Sica A. p50 nuclear 105. Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. A uniquely
factor-kappaB overexpression in tumor-associated macrophages stable replication-competent retrovirus vector achieves efficient
inhibits M1 inflammatory responses and antitumor resistance. gene delivery in vitro and in solid tumors. Human Gene Ther
Cancer Res 2006;66:11432-40. 2001;12:921-32.
94. Cao S, Liu J, Chesi M, Bergsagel PL, Ho IC, Donnelly RP, Ma X. 106. Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle
Differential regulation of IL-12 and IL-10 gene expression in suicide gene therapy by replication-competent retrovirus vectors
macrophages by the basic leucine zipper transcription factor c-Maf achieves long-term survival benefit in experimental glioma. Mol
fibrosarcoma. J Immunol 2002;169:5715-25. Ther 2005;12:842-51.
95. Ashall L, Horton CA, Nelson DE, Paszek P, Harper CV, Sillitoe K, 107. Wang W, Tai CK, Kershaw AD, Solly SK, Klatzmann D, Kasahara N,
Ryan S, Spiller DG, Unitt JF, Broomhead DS, Kell DB, Rand DA, Chen TC. Use of replication-competent retroviral vectors in an
Sée V, White MR. Pulsatile stimulation determines timing and immunocompetent intracranial glioma model. Neurosurg Focus
specificity of NF-kappaB-dependent transcription. Science 2006;20:E25.
2009;324:242-6. 108. Wang WJ, Tai CK, Kasahara N, Chen TC. Highly efficient
96. Nagasawa M. Epstein-Barr-Virus-Positive B-Cell Lymphoma and tumor-restricted gene transfer to malignant gliomas by
of Recipient Origin Despite of the Elimination of Clonally replication-competent retroviral vectors. Human Gene Ther
EBV-Infected T Cells by Allogeneic Stem Cell Transplantation in 2003;14:117-27.
a Patient with Chronic Active EBV Infection. Case Rep Transplant 109. Hickey MJ, Kasahara N, Mueller BM, Kruse CA. Combining cellular
2012;2012:164824. and gene therapy approaches for treatment of intracranial tumors.
97. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Oncoimmunology 2013;2:e25989.
Kruse CA. Cellular and vaccine therapeutic approaches for gliomas. 110. Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET,
J Transl Med 2010;8:100. Kamijima S, Inagaki A, Takahashi M, Kato Y, Kasahara N,
98. Gomez GG, Kruse CA. Isolation and Culture of Human Brain Tumor Mueller BM, Kruse CA. Combined alloreactive CTL cellular therapy
Cells. Meth Mol Med 2003;88:101-10. with prodrug activator gene therapy in a model of breast cancer
99. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, metastatic to the brain. Clin Cancer Res 2013;19:4137-48.
Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, 111. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus
Roth MD. Dendritic cell vaccination in glioblastoma patients induces Calmette-Guerin in the treatment of superficial bladder tumors.
systemic and intracranial T-cell responses modulated by the local 1976. J Urol 2002;167:891-3; discussion 893-5.
central nervous system tumor microenvironment. Clin Cancer Res 112. Böhle A, Brandau S. Immune mechanisms in bacillus
2005;11:5515-25. Calmette-Guerin immunotherapy for superficial bladder cancer.
100. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, J Urol 2003;170:964-9.
Prins RM. Monitoring of regulatory T cell frequencies and expression
of CTLA-4 on T cells, before and after DC vaccination, can predict Cite this article as: Ha ET, Antonios JP, Soto H, Prins RM, Yang I, Kasahara N,
survival in GBM patients. PloS One 2012;7:e32614. Liau LM, Kruse CA. Chronic inflammation drives glioma growth: cellular and
101. Hickey MJ, Malone CC, Erickson KE, Gomez GG, Young EL, molecular factors responsible for an immunosuppressive microenvironment.
Neuroimmunol Neuroinflammation 2014;1(2):66-76.
Liau LM, Prins RM, Kruse CA. Implementing preclinical study
findings to protocol design: translational studies with alloreactive Source of Support: Nil. Conflict of Interest: No.
CTL for gliomas. Am J Transl Res 2012;4:114-26. Received: 09-05-2014; Accepted: 21-07-2014

76 Neuroimmunol Neuroinflammation | Volume 1 | Issue 2 | September 2014